InnoCare wins China CDE approval for registrational Phase III mesutoclax — orelabrutinib trial in r/r MZL
China’s NMPA drug regulator cleared InnoCare’s registrational Phase III trial of mesutoclax with orelabrutinib in relapsed/refractory MZL. Study targets patients who received at least one prior therapy, supporting a potential label-expansion path in China. Mesutoclax-orelabrutinib holds Breakthrough Therapy Designation